U.S. Congressman Sweeney to Attend AngioDynamics Facility Expansion Ceremony
The expansion project will consist of a 36,000 square foot Warehouse and Distribution Center, which will accommodate the Company's increasing number of employees and provide a foundation for future growth of the organization. The expansion is scheduled to be completed in the spring of 2007.
Since its initial public offering in May 2004, AngioDynamics has experienced tremendous growth in revenue, profitability and number of employees and was named one of BusinessWeek's Top 100 Hot Growth Companies in both 2005 and 2006. AngioDynamics is in the heart of "Catheter Valley," part of New York State's Adirondack region and so named for its long history of catheter and other medical device manufacturing.
Congressman Sweeney was sworn into the U.S. Congress on January 6, 1999 to serve the 20th district of New York in the U.S. House of Representatives. As a member of the House Appropriations Committee, the Congressman focuses on the needs of the district and promotes economic growth. During the facility expansion ceremony, Congressman Sweeney will address the crowd and speak about healthcare issues.
"AngioDynamics is very privileged to have Congressman Sweeney attend our facility expansion ceremony," said Eamonn P. Hobbs, president and chief executive officer of AngioDynamics. "This facility expansion project will provide us with the space we need to continue developing products to treat peripheral vascular disease which are market leaders in innovation, quality, and reliability."
About AngioDynamics
AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products, and venous products. More information is available at www.angiodynamics.com.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations, competition as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company.
CONTACT: AngioDynamics, Inc.
Robert Rossell, 800-772-6446, x112
http://www.angiodynamics.com/
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
SOURCE: AngioDynamics, Inc.
